CHELMSFORD, Mass., Nov. 8, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) and the Government of Luxembourg today announced the signing of a Memorandum of Understanding ("MoU") to facilitate continued healthcare technology development in Luxembourg. The Minister of the Economy of Luxembourg, Mr. Franz Fayot, and the President and CEO of Azenta, Steve Schwartz, signed the MoU at Azenta's Massachusetts-based global headquarters. Azenta, Inc. had recently acquired B Medical Systems, a leading global vaccine, and medical cold chain provider, based in Luxembourg.
The MoU signing ceremony was attended by several senior dignitaries from the Ministry of the Economy of Luxembourg, Ministry of Higher Education and Research of Luxembourg, Luxembourg Trade and Investment Office in New York, Luxinnovation and Azenta, Inc. Mr. Luc Provost, CEO of B Medical Systems, and Mr. Jesal Doshi, Deputy CEO of B Medical Systems, represented B Medical Systems, a subsidiary of Azenta, during the ceremony.
Confirming Azenta's desire to preserve the production activities of its subsidiary in Luxembourg, B Medical Systems, and to continue the projects undertaken by the subsidiary until then, the memorandum of understanding confirms the intention of the Ministry of the Economy to continue to support the development of the company in Luxembourg. The acquisition by Azenta should also give B Medical Systems access to new markets, thanks to the group's extensive network of customers in countries where B Medical Systems has not previously had a significant presence.
The MoU signing ceremony was followed by a visit to Azenta's genomics lab in Waltham, Massachusetts by the delegation of the Ministry of Health led by the Vice Prime Minister and Minister of Health, Ms. Paulette Lenert, and the delegation of the Ministry of the Economy led by the Minister of Economy, Mr. Franz Fayot.
The Minister of the Economy Franz Fayot stated: "The fact that a world-renowned company such as Azenta has acquired B Medical Systems, one of our industrial flagships, demonstrates the dynamism of the Luxembourg health technology sector, which is one of the pillars of Luxembourg's economic diversification strategy. Through this memorandum of understanding, our objective is to continue the good collaboration that already existed with B Medical Systems, particularly in its future research, development and innovation projects, as well as to identify possible synergies."
"We look forward to continued partnership and engagement with the Government of Luxembourg. B Medical Systems, which recently became a part of Azenta, has a long history of operations in Luxembourg, and we intend to build upon this already strong track record of growth and innovation," said Steve Schwartz, President and CEO of Azenta.
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Azenta recently acquired B Medical Systems, a leading global vaccine, and medical cold chain provider, based in Luxembourg.
Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
Head of Investor Relations
SOURCE Azenta, Inc.